Today could be a major turning point for the UK biotech sector, as changes in government policy could help channel billions of new investment into drug discovery and development.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.